ZBH

#618
Zimmer Biomet Holdings, Inc. Common Stock
98.9 3 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
98.68
99.45
Intervallo Annuale
79.12
103.69
Variazione giornaliera
-0.58%
Variazione Mensile
-2.38%
Variazione di 6 mesi
+4.77%
Variazione Annuale
-4.42%
Chiusura Precedente
99.5 1
Open
98.9 8
Minimo
98.6 8
Massimo
99.4 5
Volume
583
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi Documents

2026

Current report, Q3 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
ZIMMER BIOMET HOLDINGS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
ZIMMER BIOMET HOLDINGS, INC. current report, Q1 FY2026
8-K

ZIMMER BIOMET HOLDINGS, INC. current report, Q3 FY2017

Full document

Business Context and Reporting Period

Company: ZIMMER BIOMET HOLDINGS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2017
Event: Entry into material definitive agreements regarding term loans and guarantees.

Key Financial Metrics and Debt Structure

This filing details specific debt instruments rather than operational financial performance metrics (revenue, profit, cash flow).

  • New Term Loan: Yen 21.3 billion with Sumitomo Mitsui Banking Corporation (SMBC).
  • Restated Term Loan: Yen 11.7 billion (amending a 2012 agreement) with SMBC.
  • Total Loan Amount: Yen 33.0 billion.
  • Interest Rate: Fixed at 0.635% per annum.
  • Maturity Date: September 27, 2022.
  • Guarantee: The Company has unconditionally guaranteed the Borrower's obligations.

Material Changes and Covenants

The filing reports the execution of new and amended loan agreements. Key terms incorporated from the existing Credit Agreement include:

  • Debt Ratio Covenant: The Company must maintain a consolidated indebtedness to consolidated EBITDA ratio of no greater than 4.5 to 1.0 for any fiscal quarter.
  • Investment Grade Restrictions: If the Company does not maintain Investment Grade Standing, additional restrictions apply, including limitations on investments and dividend payments.
  • Other Covenants: Standard affirmative and negative covenants for unsecured financing, including limitations on consolidations, mergers, and asset sales.

Guidance, Outlook, and Risks

Management Commentary: The filing contains no forward-looking guidance, earnings outlook, or management commentary regarding operational performance.
Risks and Contingencies: The primary risk disclosed relates to compliance with financial covenants. Failure to maintain the 4.5x debt-to-EBITDA ratio or Investment Grade Standing could trigger restrictions on capital allocation (dividends, investments).
Unusual Items: None reported in this filing.

Investor Verification Checklist

  • Verify the current consolidated indebtedness to consolidated EBITDA ratio to ensure compliance with the 4.5 to 1.0 covenant.
  • Confirm the Company's current credit rating status to determine if Investment Grade Standing restrictions are active.
  • Review the full text of the attached Exhibits 10.1, 10.2, and 10.3 for specific default events and prepayment terms.
  • Assess the impact of the Yen-denominated debt on the Company's overall currency exposure.

Notizie